eRapa (encapsulated rapamycin) Named Patient Programme
Supporting Access for Patients with Familial Adenomatous Polyposis (FAP)
About the Programme
The eRapa Named Patient Programme has been established to provide access to eRapa, an investigational oral formulation of rapamycin, for certain patients diagnosed with Familial Adenomatous Polyposis (FAP).
The programme is intended for patients:
- With serious or life‑threatening disease
- Who are unable to participate in a clinical trial
- For whom the treating physician believes treatment may be appropriate
Access is subject to local regulatory and legal requirements, medical eligibility andprogramme criteria, product availability, and applicable funding mechanisms.
About Familial Adenomatous Polyposis
Familial Adenomatous Polyposis is a rare inherited condition characterized by the development of multiple colorectal polyps, often beginning in adolescence. If untreated, FAP is associated with a high risk of colorectal cancer. Currently, there are no approved pharmacological therapies, and surgical intervention remains the standard of care in many patients.erenta trial is a Phase 3 clinical trial for people diagnosed with familial adenomatous polyposis (FAP). The purpose of this trial is to test an experimental treatment, eRapa, to evaluate its ability to improve clinical outcomes in FAP patients vs placebo (inactive substance).
About eRapa
eRapa is a proprietary oral capsule formulation of rapamycin (sirolimus). Rapamycin inhibits the mTOR pathway, which plays a role in cellular growth and proliferation and has been shown to be over‑expressed in FAP‑associated polyps.
eRapa is an investigational medicine that is currently being evaluated in clinical trials and has not been approved by any regulatory authority. Its clinical benefits and risks have not yet been fully established.
Programme Oversight
The eRapa Named Patient Programme is available on a case‑by‑case basis, requires requests to be submitted by a licensed treating physician, and is implemented in collaboration with Tanner Pharma Group, which provides compliant, controlled access services globally.
Contact Information
For information related to the eRapa Named Patient Programme, healthcare providers may contact:
Email: erapa@tannerpharma.com
Important Notice
This programme is not intended to replace participation in clinical trials where such participation is feasible. Biodexa may modify or discontinue the programme in accordance with applicable regulations.